Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients?

Archives of Gynecology and Obstetrics

Volumn 281, Issue 2, 2010, Pages 339-344

  Güth, Uwe ^a   Huang, Dorothy Jane ^a   Schötzau, Andreas ^b   Wight, Edward ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Schotzau and Simmen Institute for Biomathematics   (Switzerland)

Author keywords

Chemotherapy; Chronic disease; Outcome; Ovarian carcinoma; Platinum resistance; Recurrent disease

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; PLATINUM;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SENSITIVITY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; RECURRENT CANCER; TREATMENT OUTCOME; CARCINOMA; COHORT ANALYSIS; DRUG RESISTANCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PLATINUM; RETROSPECTIVE STUDIES;

EID: 77950351726     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-1159-0     Document Type: Article

References (17)

1. Ozols R, Rubin S, Thomas G, Robboy S (2005) Epithelial ovarian cancer. In: Hoskins W, Perez C, Young R (eds) Principles and practice of gynecologic oncology. Lippincott Williams & Wilkins, Philadelphia, pp 895-987
2. Bukowski RM, Ozols RF, Markman M (2007) The management of recurrent ovarian cancer. Semin Oncol 34:S1-S15 (Pubitemid 46745307)
3. Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [see comments]. Ann Oncol 8:963-968 (Pubitemid 27475726)
4. Ozols RF (1997) Treatment of recurrent ovarian cancer: increasing options-"recurrent" results. J Clin Oncol 15:2177-2180 (Pubitemid 27251116)
5. Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinumbased chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106
6. Markman M (2006) Unresolved issues in the chemotherapeutic management of gynecologic malignancies. Semin Oncol 33:S33-S38 (Pubitemid 43729193)
7. Michener CM, Belinson JL (2005) Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease. Oncology (Williston Park) 19:1277-1285 discussion 1285, 1288, 1293
8. Güth U, Kann SR, Huang DJ et al (2009) Systemic therapy developments and their Effects regarding the current concept of recurrent ovarian carcinoma as a chronic disease. Arch Gynecol Obstet [Epub ahead of print]
9. Lubkin I, Larsen P (2002) Chronic illness. Jones & Bartlett, Sudbury
10. Norris S, Glasgow R, Engelgau M et al (2003) Chronic disease management: a deWnition and systematic approach to component interventions. Dis Manag Health Outcomes 11:477-488 (Pubitemid 37056112)
11. Pectasides D, Psyrri A, Pectasides M, Economopoulos T (2006) Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert Opin Pharmacother 7:975-987 (Pubitemid 43949937)
12. Rocconi RP, Case AS, Straughn JM Jr et al (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer 107:536-543 (Pubitemid 44107214)
13. Herzog TJ (2006) The current treatment of recurrent ovarian cancer. Curr Oncol Rep 8:448-454 (Pubitemid 44697774)
14. Modesitt SC, Jazaeri AA (2007) Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother 8:2293-2305 (Pubitemid 350001591)
15. Fung-Kee-Fung M, Oliver T, Elit L et al (2007) Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 14:195-208
16. Ozols RF (2006) Challenges for chemotherapy in ovarian cancer. Ann Oncol 17(Suppl 5):v181-v187
17. Markman M (2001) Why study third-, fourth-, fifth-line chemotherapy of ovarian cancer? Gynecol Oncol 83:449-450 (Pubitemid 33139701)